| Literature DB >> 28677758 |
Xin-Jie Bao1, Geng-Chao Wang2, Fu-Xing Zuo3, Xue-Yuan Li1, Jun Wu4, Guo Chen4, Wan-Chen Dou1, Yi Guo1, Qin Shen4, Ren-Zhi Wang1.
Abstract
Adult neurogenesis in the subventricular zone (SVZ), as well as in the subgranular zone contributes to brain maintenance and regeneration. In the adult brain, dopamine (DA) can regulate the endogenous neural stem cells within these two regions, while a DA deficit may affect neurogenesis. Notably, the factors that regulate in vivo neurogenesis in these subregions have not yet been fully characterized, particularly following DA depletion. In thi study, we performed RNA sequencing to investigate transcriptomic changes in the SVZ and dentate gyrus (DG) of mice in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This analysis identified differentially expressed genes which were involved in the regulation of transcription, immune response, extracellular region, cell junction and myelination. These genes partially displayed different temporal profiles of expression, some of which may participate in the metabolic switch related to neurogenesis. Additionally, the mitogen‑activated protein kinase (MAPK) signaling pathway was shown to be been positively regulated in the SVZ, while it was negatively affected in the DG following MPTP administration. Overall, our findings indicate that exposure to MPTP may exert different effects on transcriptome profiling between the SVZ and DG.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28677758 PMCID: PMC5547956 DOI: 10.3892/ijmm.2017.3052
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101
Figure 1Behavioral tests and immunostaining of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra (SN). No significant difference in motor performance in mice was observed in the (A) rotarod or (B) pole test prior to exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Notably, mice administered MPTP exhibited a significant deterioration in locomotor activity 21 days after the intraperitoneal injection of the neurotoxin compared to the saline-treated controls, or the baseline. Values represent the means ± SEM of 4–6 mice/group (*p<0.05; two-way ANOVA). When compared with the (C) saline-injected control, there was a marked reduction in TH immunoreactivity at the level of the SN in the (D) mice administered MPTP. Scale bars represent 300 µm. (E) Stereological analysis revealed a significantly greater reduction in the number of nigral TH-positive neurons of MPTP-exposed mice compared to the control animals 21 days after administration. Scale bars represent the means ± SEM of 4–6 mice/group (*p<0.05; two-tailed Student's t-test).
Figure 2Ultrastructural analysis of neuronal alteration and axonal degeneration following exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by transmission electron microscopy. Neuronal structures in the (A) substantia nigra (SN) and (B) axons in the striatum appeared normal in animals not administered MPTP. (C) A dying neuron in the SN from the MPTP-exposed group. Plasma membrane appeared ruptured and organelles were largely destroyed. Perinuclear cytoplasm was severely dilated including endoplasmic reticulum (ER) (arrows). (D) Axonal degeneration with increased endoneurial space was identified in the striatum of mice administered MPTP. Dystrophic myelinated axons swelled (asterisks), containing disintegrating mitochondria, but without disruption of myelin sheath. Dashed box in (D) indicates the location of the magnified view of surrounding neuropil (E). One enlarged axonal mitochondrion appeared in a ring-like shape (arrow in E) close to a normal-sized mitochondrion. Note the aberrant mitochondrion (black arrow in F) with residual cristae (black arrowheads in F). In addition, the aggregation of filamentous material was observed in the myelinated axon (white arrowhead in F). Scale bars represent 10 µm in (A–D) and 2 µm in (E and F).
Figure 3Gene expression signature in the subventricular zone (SVZ) and dentate gyrus (DG) 4 days and 3 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. Hierarchical cluster analysis performed on genes significantly altered in the (A) SVZ and (B) DG following exposure to MPTP (FPKM >1, fold change >1 or <−1, q-value <0.05). The cluster graphs were obtained using correlation (uncentered) similarity metric and centroid linkage clustering methods with Gene Cluster 3.0 software. The green probes correspond to downregulated genes, and the red ones corresponded to upregulated genes.
Figure 4Gene expression patterns and Web Gene Ontology Annotation Plot (WEGO) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed subventricular zone (SVZ) at different time points. (A) Identification of MPTP-induced changes in gene expression in the SVZ corresponding to the different temporal expression profiles. There were two different gene expression patterns: i) cluster A, genes with long-lasting upregulation throughout the experimental periods [pyruvate dehydrogenase kinase, isozyme 4 (Pdk4) and G protein-coupled receptor 17 (Gpr17)]; followed by ii) cluster B, genes with a significant decrease at the early stage but further overrepresented 3 weeks after MPTP [nuclear receptor subfamily 4, group A, member 3 (Nr4a3), Fos-like antigen 2 (Fosl2), early growth response 2 (Egr2), Egr4 and solute carrier family 17 (vesicular glutamate transporter), member 7 (Slc17a7)]. (B) The annotation analysis of transcriptomic changes in the SVZ was plotted and compared between two datasets of day 4 and week 3 by WEGO. Gene Ontology (GO) pathways with >3 genes were considered significant and included in the figure. In this histogram, significantly differential genes (FPKM >1, fold change >1 or <−1, q-value <0.05) were compared between the day 4 and week 3 group.
Figure 5Gene Ontology (GO) analysis, including cellular component (yellow), molecular function (blue) and biological process (red) of transcriptomic changes in the (A) subventricular zone (SVZ) and (B) dentate gyrus (DG) 3 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. The analysis was performed using the functional annotation tool of the David bioinformatics database. GO pathways with >3 genes were considered significant if fold enrichment was >2-fold and the p-value <0.05. The vertical and horizontal axes were the GO terms and the logarithm of p-values, respectively. Improtantly, some functions observed in the SVZ after MPTP intoxication were enhanced (e.g., positive regulation of transcription, transmission of nerve impulse, and myelination), while others were inversely affected (e.g., cell adhesion). In the DG, those functions with considerable activation were identified, including cell junction, synapse and fatty acid transport. Nevertheless, transcription activator activity, mitogen-activated protein (MAP) kinase phosphatase activity, extracellular region, and positive regulation of transcription were significantly downregulated.
Selected genes differentially expressed in the SVZ of mice 3 weeks after MPTP exposure.
| Accession no. | Gene symbol | Gene name | FC | q-value |
|---|---|---|---|---|
| Genes related with molecular function | ||||
| GOTERM_MF_FAT transcription factor activity, 8 genes, p-value 7.76E-3 | ||||
| NM_010234 | FBJ osteosarcoma oncogene | 1.30 | 0.011 | |
| NM_001077364 | TSC22 domain family, member 3 | 1.19 | 0.011 | |
| NM_010118 | Early growth response 2 | 1.69 | 0.011 | |
| NM_008037 | Fos-like antigen 2 | 3.06 | 0.011 | |
| NM_001110850 | cAMP responsive element modulator | 1.06 | 0.040 | |
| NM_010444 | Nuclear receptor subfamily 4, group A, member 1 | 1.68 | 0.011 | |
| NM_001307989 | Nuclear receptor subfamily 4, group A, member 3 | 3.60 | 0.011 | |
| NM_008036 | FBJ osteosarcoma oncogene B | 1.14 | 0.011 | |
| Genes related with biological process | ||||
| GOTERM_BP_FAT transmission of nerve impulse, 5 genes, p-value 0.033 | ||||
| NM_182993 | Solute carrier family 17, member 7 | 2.52 | 0.011 | |
| NM_007657 | CD9 antigen | 2.06 | 0.011 | |
| NM_010118 | Early growth response 2 | 1.69 | 0.011 | |
| NM_001205075 | Prepronociceptin | 1.44 | 0.019 | |
| NM_011674 | UDP galactosyltransferase 8A | 1.17 | 0.011 | |
| GOTERM_BP_FAT regulation of membrane potential, 4 genes, p-value 0.026 | ||||
| NM_007657 | CD9 antigen | 2.06 | 0.011 | |
| NM_010118 | Early growth response 2 | 1.69 | 0.011 | |
| NM_011674 | UDP galactosyltransferase 8A | 1.17 | 0.011 | |
| NM_001112813 | Calcium channel, voltage-dependent, T type, α 1G subunit | −1.05 | 0.019 | |
| GOTERM_BP_FAT axon ensheathment, 3 genes, p-value 0.019 | ||||
| NM_007657 | CD9 antigen | 2.06 | 0.011 | |
| NM_010118 | Early growth response 2 | 1.69 | 0.011 | |
| NM_011674 | UDP galactosyltransferase 8A | 1.17 | 0.011 | |
| GOTERM_BP_FAT myelination, 3 genes, p-value 0.017 | ||||
| NM_007657 | CD9 antigen | 2.06 | 0.011 | |
| NM_010118 | Early growth response 2 | 1.69 | 0.011 | |
| NM_011674 | UDP galactosyltransferase 8A | 1.17 | 0.011 | |
Genes were grouped in 5 functional categories: transcription factor activity, transmission of nerve impulse, regulation of membrane potential, axon ensheathment and myelination. Note that some genes were included in several categories. Gene function was attributed using DAVID bioinformatics database for clustering by functional annotation, and the number of genes and p-value of each biological function were included. FC represents the fold change between gene expressions of MPTP-exposed mice vs. saline-infused animals. SVZ, subventricular zone; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Selected genes differentially expressed in the DG of mice 3 weeks after MPTP exposure.
| Accession no. | Gene symbol | Gene name | FC | q-value |
|---|---|---|---|---|
| Genes related with molecular function | ||||
| GOTERM_MF_FAT transcription activator activity, 7 genes, p-value 2.22E-3 | ||||
| NM_007913 | Early growth response 1 | −1.55 | 0.006 | |
| NM_207225 | Histone deacetylase 4 | 1.16 | 0.010 | |
| NM_010444 | Nuclear receptor subfamily 4, group A, member 1 | −1.77 | 0.006 | |
| NM_019740 | Forkhead box O3 | 1.20 | 0.006 | |
| NM_001307989 | Nuclear receptor subfamily 4, group A, member 3 | 1.01 | 0.010 | |
| NM_011141 | POU domain, class 3, transcription factor 1 | −3.65 | 0.006 | |
| NM_153553 | Neuronal PAS domain protein 4 | −2.04 | 0.006 | |
| Genes related with cellular component | ||||
| GOTERM_CC_FAT synapse, 7 genes, p-value 4.14E-3 | ||||
| NM_207225 | Histone deacetylase 4 | 1.16 | 0.010 | |
| NM_001276684 | Activity regulated cytoskeletal-associated protein | −1.67 | 0.006 | |
| NM_008067 | Gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 | −1.12 | 0.006 | |
| NM_008069 | Gamma-aminobutyric acid (GABA) A receptor, subunit beta 1 | 1.02 | 0.006 | |
| NM_008170 | Glutamate receptor, ionotropic, NMDA2A (ε1) | 1.02 | 0.006 | |
| NM_009229 | Syntrophin, basic 2 | 1.18 | 0.006 | |
| NM_029210 | Synaptic vesicle glycoprotein 2c | 1.46 | 0.006 | |
| GOTERM_CC_FAT extracellular region, 19 genes, p-value 6.37E-4 | ||||
| NM_001313969 | Vasoactive intestinal polypeptide | −1.06 | 0.033 | |
| NM_001159487 | Retinol binding protein 4, plasma | −2.16 | 0.027 | |
| NM_008940 | Kallikrein related-peptidase 8 | −1.33 | 0.020 | |
| NM_198408 | Corticotropin releasing hormone binding protein | −1.99 | 0.006 | |
| NM_177059 | Follistatin-like 4 | 1.06 | 0.043 | |
| NM_008597 | Matrix Gla protein | −1.43 | 0.022 | |
| NM_001122736 | Insulin-like growth factor 2 | −2.00 | 0.006 | |
| NM_001190451 | Decorin | −1.77 | 0.006 | |
| NM_183136 | Serine peptidase inhibitor, Kazal type 8 | −2.29 | 0.006 | |
| NM_009177 | ST3 beta-galactoside α-2,3-sialyltransferase 1 | 1.02 | 0.006 | |
| NM_010930 | Nephroblastoma overexpressed gene | −4.57 | 0.006 | |
| NM_008963 | Prostaglandin D2 synthase (brain) | −1.73 | 0.006 | |
| NM_001301353 | Apolipoprotein D | −1.31 | 0.006 | |
| NM_022312 | Tenascin-R | 1.02 | 0.006 | |
| NM_030890 | Proline-rich transmembrane protein 1 | 1.01 | 0.006 | |
| NM_139298 | Wingless-type MMTV integration site family, member 9A | −1.06 | 0.006 | |
| NM_007729 | Collagen, type XI, α1 | −1.08 | 0.020 | |
| NM_010517 | Insulin-like growth factor binding protein 4 | −1.22 | 0.006 | |
| NM_012045 | Phospholipase A2, group IIF | 1.28 | 0.006 | |
| GOTERM_CC_FAT cell junction, 8 genes, p-value 7.00E-3 | ||||
| NM_001276684 | Activity regulated cytoskeletal-associated protein | −1.67 | 0.006 | |
| NM_021424 | Poliovirus receptor-related 1 | 1.18 | 0.006 | |
| NM_008067 | Gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 | −1.12 | 0.006 | |
| NM_008069 | Gamma-aminobutyric acid (GABA) A receptor, subunit beta 1 | 1.02 | 0.006 | |
| NM_008170 | Glutamate receptor, ionotropic, NMDA2A (ε1) | 1.02 | 0.006 | |
| NM_009229 | Syntrophin, basic 2 | 1.18 | 0.006 | |
| NM_001083119 | Protein tyrosine phosphatase, receptor type, U | −1.31 | 0.006 | |
| NM_029210 | Synaptic vesicle glycoprotein 2c | 1.46 | 0.006 | |
| Genes related with biological process | ||||
| GOTERM_BP_FAT embryonic organ development, 5 genes, p-value 0.024 | ||||
| NM_001159487 | Retinol binding protein 4, plasma | −2.16 | 0.027 | |
| NM_001307989 | Nuclear receptor subfamily 4, group A, member 3 | 1.01 | 0.010 | |
| NM_139298 | Wingless-type MMTV integration site family, member 9A | −1.06 | 0.006 | |
| NM_008937 | Prospero homeobox 1 | 1.01 | 0.006 | |
| NM_007729 | Collagen, type XI, α1 | −1.08 | 0.020 | |
| GOTERM_BP_FAT positive regulation of transcription, 11 genes, p-value 5.21E-5 | ||||
| NM_009538 | Pleiomorphic adenoma gene-like 1 | 1.28 | 0.006 | |
| NM_007913 | Early growth response 1 | −1.55 | 0.006 | |
| NM_010234 | FBJ osteosarcoma oncogene | −1.77 | 0.006 | |
| NM_207225 | Histone deacetylase 4 | 1.16 | 0.010 | |
| NM_001305671 | GLIS family zinc finger 3 | 1.25 | 0.006 | |
| NM_001136072 | Meis homeobox 2 | −2.37 | 0.006 | |
| NM_010444 | Nuclear receptor subfamily 4, group A, member 1 | −1.77 | 0.006 | |
| NM_019740 | Forkhead box O3 | 1.20 | 0.006 | |
| NM_001307989 | Nuclear receptor subfamily 4, group A, member 3 | 1.01 | 0.010 | |
| NM_011141 | POU domain, class 3, transcription factor 1 | −3.65 | 0.006 | |
| NM_153553 | Neuronal PAS domain protein 4 | −2.04 | 0.006 | |
Genes were grouped into 6 functional categories: transcription activator activity, synapse, extracellular region, cell junction, embryonic organ development and positive regulation of transcription. Note that some genes were included in several categories. Gene function was attributed using DAVID bioinformatics database for clustering by functional annotation, and the number of genes and p-value of each biological function were included. FC represents the fold change between gene expressions of MPTP-exposed mice vs. saline-infused animals. DG, dentate gyrus; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Figure 6Synopsis of significant mitogen-activated protein kinase (MAPK) signaling pathway in the subventricular zone (SVZ) of mice exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Specifically, related genes were upregulated (red) such as FBJ murine osteosarcoma viral oncogene homolog (Fos), and nuclear receptor subfamily 4, group A, member 1 (Nr4a1).
Figure 7Synopsis of significant mitogen-activated protein kinase (MAPK) signaling pathway in the dentate gyrus (DG) of mice exposed to MPTP according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Notably, MPTP intoxication was associated with decreased expression of genes (blue) involved in transcription [FBJ murine osteosarcoma viral oncogene homolog (Fos), and nuclear receptor subfamily 4, group A, member 1 (Nr4a1)] and MAPK phosphatase activity [dual specificity phosphatase 1 (Dusp1) and Dual specificity phosphatase 6 (Dusp6)].